Virbac S.A (VIRP) | Stock Overview & Key Data
Virbac S.A. | Large-cap | Healthcare
Virbac S.A. | Large-cap | Healthcare
Virbac S.A Performance Comparison
Stock Range
Today's Range
Low: €339.50
High: €341.50
on August 21, 2025
52 Week Range
Low: €249.70
High: €400.00
on April 7, 2025
on September 19, 2024
All-Time High: €448.50 on November 1, 2021
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€2.9B
EPS
17.36
P/E Ratio (TTM)
19.67
Forward P/E
17.20
P/B Ratio
2.74
PEG Ratio
17.20
Div. Yield
0.80%
ROE
14.93%
Beta
0.830
Debt to Equity
29.98
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
11.52%
Profit Margin
10.40%
Returns and Earnings
Return on Assets (TTM)
8.66%
Return on Equity (TTM)
14.93%
EBITDA
€289.8M
Net Income (TTM)
€145.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€166.86
Quarterly Revenue Growth (YoY)
9.10%
Quarterly Earnings Growth (YoY)
9.40%
Dividend Information
Last 12-Month Dividend
€2.57
Current Dividend Yield
0.80%
3-Year Average Dividend Yield
0.42%
3-Year Average Annual Dividend
€1.30
3-Year Total Dividends
€3.89
Ex-Dividend Date
June 24, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Virbac S.A VIRP | 2.86B Large-cap | 3.18% | -2.71% | 9.29% | 9.47% | 6.90% | -0.29% | -8.70% | 81.77% |
| Sanofi SAN | N/A | 4.70% | 6.28% | -6.70% | -15.99% | -7.26% | -12.83% | 6.81% | 2.87% |
| EssilorLuxottica EL | 123.50B Large-cap | 3.38% | 11.70% | 4.45% | -6.50% | 16.14% | 26.57% | 79.07% | 139.75% |
| Sartorius Stedim DIM | 17.27B Large-cap | -0.40% | -7.43% | -11.07% | -13.75% | -4.75% | -0.65% | -53.41% | -40.52% |
| bioMérieux S.A BIM | 14.97B Large-cap | 0.71% | 7.60% | 6.97% | 13.24% | 24.05% | 23.21% | 21.51% | 1.92% |
| Eurofins Scientific ERF | 11.97B Large-cap | 0.71% | 10.43% | 20.23% | 39.34% | 39.43% | 30.27% | -4.28% | 3.03% |
Ownership & Short Interest
Insider Ownership
50.81%
Institutional Ownership
24.53%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
3K
Average 90-Day Volume
4K
Virbac S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Virbac S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VIRP's 52-week high and low?
- In the last 52 weeks, Virbac S.A reached a high of €400.00 (on September 19, 2024) and a low of €249.70 (on April 7, 2025).
- What is the market cap and P/E ratio for VIRP?
- Curious about Virbac S.A's size and valuation? Its market capitalization stands at 2.86B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.67, and the forward P/E (looking ahead) is 17.20.
- Does VIRP pay dividends? If so, what's the yield?
- Yes, Virbac S.A is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.80%, and the company has paid an average of €1.30 per share annually over the past 3 years.
- Who are Virbac S.A's main competitors or similar companies to consider before investing?
When looking at Virbac S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sanofi
SANN/A Healthcare Drug Manufacturers - General -12.83% 6.81% EssilorLuxottica
EL123.50B Healthcare Medical Instruments & Supplies 26.57% 79.07% Sartorius Stedim
DIM17.27B Healthcare Medical Instruments & Supplies -0.65% -53.41% bioMérieux S.A
BIM14.97B Healthcare Diagnostics & Research 23.21% 21.51% Eurofins Scientific
ERF11.97B Healthcare Diagnostics & Research 30.27% -4.28% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Virbac S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Virbac S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.93%, the Debt to Equity ratio from the most recent quarter is 29.98, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for VIRP?
- Looking at Virbac S.A's growth, its revenue over the trailing twelve months (TTM) was €1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.10%, and quarterly earnings saw a YoY growth of 9.40%.
- How much of VIRP stock is held by insiders and institutions?
- Wondering who owns Virbac S.A stock? Company insiders (like executives and directors) hold about 50.81% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 24.53%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.